STOCK B2m^tm1Unc Cd4^tm1Litt H2-Ab1^b-tm1Doi Tg(Cd4-CD4)2362Litt Tg(Cd4-EGFP) Tg(H2-Aa-HLA-DPA1)1Lone Tg(H2-Ab1-HLA-DPB1)1Lone Tg(HLA-A/H2-D/B2M)1Bpe/Orl

Status	Available to order
EMMA ID	EM:06321
International strain name	STOCK B2m^tm1Unc Cd4^tm1Litt H2-Ab1^b-tm1Doi Tg(Cd4-CD4)2362Litt Tg(Cd4-EGFP) Tg(H2-Aa-HLA-DPA1)1Lone Tg(H2-Ab1-HLA-DPB1)1Lone Tg(HLA-A/H2-D/B2M)1Bpe/Orl
Alternative name	Hsurivong/CD4-EGFP
Strain type	Transgenic Strains
Allele/Transgene symbol	Tg(Cd4-EGFP)1Lt, H2-Ab1^b-tm1Doi, B2m^tm1Unc, Cd4^tm1Litt, Tg(HLA-A/H2-D/B2M)1Bpe, Tg(Cd4-CD4)2362Litt, Tg(H2-Aa-HLA-DPA1)1Lone, Tg(H2-Ab1-HLA-DPB1)1Lone
Gene/Transgene symbol	Tg(Cd4-EGFP)1Lt, H2-Ab1, B2m, Cd4, Tg(HLA-A/H2-D/B2M)1Bpe, Tg(Cd4-CD4)2362Litt, Tg(H2-Aa-HLA-DPA1)1Lone, Tg(H2-Ab1-HLA-DPB1)1Lone

Information from provider

Provider	Yu Chun LONE
Provider affiliation	INSERM U1014
Genetic information	A transgenic construct containing an enhanced green florescent protein cDNA fused to the murine Cd4 promoter as described by Reifsnyder P & al (PubMed: 10570176) was injected into Hsurivong (EM:02221) mouse eggs. Founder line was then mated to Sure-L1 (EM:01783) mice until homozygous.
Phenotypic information	HLA-A2+/+; HLA-DP4+/+; IAbeta°/°; Beta2m°/°; mCD4°/°; hCD4+/+; CD4-GFP+/+
References	Development of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein.;Ru Zhitao, Xiao Wenjun, Pajot Anthony, Kou Zhihua, Sun Shihui, Maillere Bernard, Zhao Guangyu, Ojcius David M, Lone Yu-Chun, Zhou Yusen, ;2012;PloS one;7;e32247; 22403638
Homozygous fertile	yes
Homozygous viable	yes
Homozygous matings required	yes
Immunocompromised	no

Information from EMMA

Archiving centre	Institut de Transgenose, INTRAGENE, Orléans, France
Animals used for archiving	homozygous C57BL/6J, homozygous C57BL/6J
Stage of embryos	2-cell

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

Immunodeficiency by defective expression of MHC class I / Orphanet_34592
Variant ABeta2M amyloidosis / Orphanet_314652

IMPC phenotypes (gene matching)

preweaning lethality, incomplete penetrance / IMPC
preweaning lethality, complete penetrance / IMPC
small superior vagus ganglion / IMPC
embryonic lethality prior to tooth bud stage / IMPC
abnormal skin morphology / IMPC
hydrometra / IMPC
increased circulating phosphate level / IMPC

MGI phenotypes (allele matching)

decreased level of surface class I molecules / MGI
decreased CD8-positive, alpha-beta T cell number / MGI
decreased IgG level / MGI
abnormal pancreas morphology / MGI
decreased susceptibility to bacterial infection / MGI
increased IgM level / MGI
decreased susceptibility to autoimmune diabetes / MGI
decreased circulating serum albumin level / MGI
increased T-helper 1 cell number / MGI
abnormal interleukin level / MGI
abnormal tumor necrosis factor level / MGI
increased susceptibility to infection induced morbidity/mortality / MGI
absent CD8-positive, alpha-beta T cells / MGI
abnormal pancreatic beta cell morphology / MGI
abnormal T cell number / MGI
insulitis / MGI
absent CD4-positive, alpha beta T cells / MGI
decreased T cell proliferation / MGI
abnormal CD4-positive, alpha-beta T cell physiology / MGI
decreased CD4-positive, alpha beta T cell number / MGI
increased CD8-positive, alpha-beta T cell number / MGI

MGI phenotypes (gene matching)

absent CD8-positive, alpha-beta T cells / MGI
decreased IgG level / MGI
decreased level of surface class I molecules / MGI
abnormal pancreas morphology / MGI
decreased susceptibility to bacterial infection / MGI
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology / MGI
increased IgM level / MGI
insulitis / MGI
abnormal lateral geniculate nucleus morphology / MGI
decreased susceptibility to autoimmune diabetes / MGI
decreased susceptibility to parasitic infection / MGI
abnormal cytotoxic T cell physiology / MGI
abnormal pancreatic beta cell morphology / MGI
decreased circulating serum albumin level / MGI
hemochromatosis / MGI
abnormal T cell number / MGI
decreased CD8-positive, alpha-beta T cell number / MGI
increased T-helper 1 cell number / MGI
increased gamma-delta T cell number / MGI
increased gamma-delta intraepithelial T cell number / MGI
increased tumor necrosis factor secretion / MGI
increased interleukin-3 secretion / MGI
decreased interleukin-4 secretion / MGI
abnormal interleukin level / MGI
abnormal tumor necrosis factor level / MGI
increased susceptibility to infection induced morbidity/mortality / MGI
abnormal spleen morphology / MGI
demyelination / MGI
decreased IgG level / MGI
decreased IgM level / MGI
brain inflammation / MGI
abnormal T cell differentiation / MGI
no abnormal phenotype detected / MGI
abnormal lymph node T cell domain morphology / MGI
abnormal double-positive T cell morphology / MGI
increased susceptibility to viral infection / MGI
abnormal CD4-positive, alpha beta T cell morphology / MGI
decreased immunoglobulin level / MGI
abnormal immune system organ morphology / MGI
no phenotypic analysis / MGI
absent CD4-positive, alpha beta T cells / MGI
abnormal T cell subpopulation ratio / MGI
abnormal bile salt level / MGI
decreased susceptibility to autoimmune diabetes / MGI
abnormal CD8-positive, alpha beta T cell morphology / MGI
decreased T cell number / MGI
increased susceptibility to parasitic infection / MGI
increased double-positive T cell number / MGI
decreased double-positive T cell number / MGI
decreased T cell proliferation / MGI
immune system phenotype / MGI
abnormal CD4-positive, alpha-beta T cell physiology / MGI
increased CD4-positive, alpha beta T cell number / MGI
decreased CD4-positive, alpha beta T cell number / MGI
increased CD8-positive, alpha-beta T cell number / MGI
absent plasma cells / MGI
impaired humoral immune response / MGI
abnormal immune system morphology / MGI
abnormal spleen morphology / MGI
abnormal immune system cell morphology / MGI
hemolytic anemia / MGI
postnatal growth retardation / MGI
abnormal immune system physiology / MGI
abnormal humoral immune response / MGI
decreased IgG level / MGI
decreased IgM level / MGI
autoimmune response / MGI
reduced fertility / MGI
premature death / MGI
abnormal T cell differentiation / MGI
no abnormal phenotype detected / MGI
abnormal spleen periarteriolar lymphoid sheath morphology / MGI
abnormal spleen marginal zone morphology / MGI
abnormal dendritic cell physiology / MGI
abnormal CD4-positive, alpha beta T cell morphology / MGI
abnormal T cell physiology / MGI
abnormal dendritic cell antigen presentation / MGI
abnormal B cell physiology / MGI
abnormal immunoglobulin level / MGI
increased IgM level / MGI
abnormal immune system organ morphology / MGI
increased urine protein level / MGI
abnormal cytokine secretion / MGI
abnormal artery development / MGI
abnormal response/metabolism to endogenous compounds / MGI
absent CD4-positive, alpha beta T cells / MGI
abnormal lymphocyte physiology / MGI
insulitis / MGI
increased anti-double stranded DNA antibody level / MGI
increased anti-single stranded DNA antibody level / MGI
increased anti-erythrocyte antigen antibody level / MGI
decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
decreased susceptibility to experimental autoimmune myasthenia gravis / MGI
decreased regulatory T cell number / MGI
increased B cell number / MGI
decreased susceptibility to parasitic infection / MGI
increased susceptibility to parasitic infection / MGI
abnormal level of surface class II molecules / MGI
increased double-negative T cell number / MGI
decreased susceptibility to autoimmune disorder / MGI
cardiovascular system phenotype / MGI
immune system phenotype / MGI
abnormal CD4-positive, alpha-beta T cell physiology / MGI
abnormal response to transplant / MGI
increased CD4-positive, alpha beta T cell number / MGI
decreased CD4-positive, alpha beta T cell number / MGI
increased CD8-positive, alpha-beta T cell number / MGI
decreased CD8-positive, alpha-beta T cell number / MGI
decreased single-positive T cell number / MGI
abnormal spleen B cell follicle morphology / MGI
absent spleen germinal center / MGI
decreased IgG1 level / MGI
decreased tumor necrosis factor secretion / MGI
decreased interleukin-12 secretion / MGI
abnormal lymph node cell ratio / MGI
abnormal neuron proliferation / MGI

Literature references

Development of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein.;Ru Zhitao, Xiao Wenjun, Pajot Anthony, Kou Zhihua, Sun Shihui, Maillere Bernard, Zhao Guangyu, Ojcius David M, Lone Yu-Chun, Zhou Yusen, ;2012;PloS one;7;e32247; 22403638

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740^*
Rederivation of mice from frozen stock, delivery time available upon request . €3880^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.

STOCK B2mtm1Unc Cd4tm1Litt H2-Ab1b-tm1Doi Tg(Cd4-CD4)2362Litt Tg(Cd4-EGFP) Tg(H2-Aa-HLA-DPA1)1Lone Tg(H2-Ab1-HLA-DPB1)1Lone Tg(HLA-A/H2-D/B2M)1Bpe/Orl